MindBio Therapeutics Corp. have started pre-screening for participant entry into Phase 2 LSD-Microdosing clinical trials. The clinical trials are a world first with approvals for take home use of MindBio's LSD-Microdosing treatment.

The initial Phase 2a open label trial will assess the treatment in patients with Major Depressive Disorder for 8 weeks. MindBio's LSD- Microdosing clinical trials to date have yielded positive top line data such as improved quality of sleep including REM and total time of sleep and statistically significant enhancements in subjective feelings of "wellness", "creativity", "h happiness", " social connectivity" and "energy". Participants in the LSD-Microdosing group also reported statistically significant feelings of being less "angry" and less "irritable".

The data collected from the trial adds to MindBio's intellectual property in a Big Data play for the Company. MindBio has developed proprietary formulations for microdosing including safe delivery solutions for ease of prescription and safe home use and a digital intervention for monitoring and collecting live biometric data whilst clinical trial participants take their LSD-Microdosing at home. The Company's Big Data strategy is to commercialize microdosing treatments with a package of proprietary solutions for safe and effective at home use of psychedelics.

MindBio remains the only organization in the world approved for take-home use of LSD-Microdosing in clinical trials providing it with a global first mover advantage. The take home approvals are vital for testing the ecological validity of MindBio's proprietary solutions as the Company progresses its commercialization strategy for global regulatory approvals. MindBio's investment thesis, using microdosing, centers on the creation of a unique treatment model that is globally scalable, safe, accessible, and affordable, aiming to address the existing challenges in mental health care and also caters for the diversity of medical regulatory regimes around the world.